First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Labcorp

    LH · 6 developments mapped · last assessed 2026-09-11

    Market Ontology has mapped 6 macro, policy, and market developments to Labcorp since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for LH yet, so no modelled value is shown. The LH valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run LH on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for LH. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M

      Increased competition in the early-phase clinical research market from a strengthened Fortrea, potentially impacting market share or pricing power.

      · Moves market share in clinical research services, pricing power in early phase trials

    What changed, by assumption

    Market share in clinical research services
    • 2026-09-03Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
    Market share
    • 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M
    • 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Million
    Market share in early phase cro services
    • 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Million
    Revenue growth rate
    • 2026-09-11GMR Solutions Inc. Secures Commitments for $2.9 Billion Term Loan Repricing and $200 Million Debt Paydown
    Competitive landscape in clinical research services
    • 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-11GMR Solutions Inc. Secures Commitments for $2.9 Billion Term Loan Repricing and $200 Million Debt Paydownwatch3-12m0.20
    2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45Mwatch3-12m0.20
    2026-09-03Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45Mwatch3-12m0.30
    2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45Mmixed3-12m0.30
    2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Division for $45 Millionmixed3-12m0.30
    2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45 Millionmixed3-12m0.30